Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Resemblance of the human liver sinusoid in a fluidic device with biomedical and pharmaceutical applications

  • Ortega-Ribera, Martí
  • Fernández-Iglesias, Anabel
  • Illa, Xavi
  • Moya, Ana
  • Molina, Víctor
  • Maeso-Díaz, Raquel
  • Fondevila, Constantino
  • Peralta, Carmen
  • Bosch, Jaume
  • Villa, Rosa
  • Gracia-Sancho, Jordi
Maintenance of the complex phenotype of primary hepatocytes in vitro represents a limitation for developing liver support systems and reliable tools for biomedical research and drug screening. We herein aimed at developing a biosystem able to preserve human and rodent hepatocytes phenotype in vitro based on the main characteristics of the liver sinusoid: unique cellular architecture, endothelial biodynamic stimulation, and parenchymal zonation. Primary hepatocytes and liver sinusoidal endothelial cells (LSEC) were isolated from control and cirrhotic human or control rat livers and cultured in conventional in vitro platforms or within our liver-resembling device. Hepatocytes phenotype, function, and response to hepatotoxic drugs were analyzed. Results evidenced that mimicking the in vivo sinusoidal environment within our biosystem, primary human and rat hepatocytes cocultured with functional LSEC maintained morphology and showed high albumin and urea production, enhanced cytochrome P450 family 3 subfamily A member 4 (CYP3A4) activity, and maintained expression of hepatocyte nuclear factor 4 alpha (hnf4α) and transporters, showing delayed hepatocyte dedifferentiation. In addition, differentiated hepatocytes cultured within this liver-resembling device responded to acute treatment with known hepatotoxic drugs significantly different from those seen in conventional culture platforms. In conclusion, this study describes a new bioengineered device that mimics the human sinusoid in vitro, representing a novel method to study liver diseases and toxicology., Funding text 1 This study was carried out at the Esther Koplowitz Center—IDIBAPS. The fabrication of Exoliver was performed by the platform of Production of Biomaterials and Biomolecules of the ICTS “NANBIOSIS,” more specifically by the U8 Unit of the CIBER in Bioengineering, Biomaterials & Nanomedicine (CIBERBBN) at the IMB-CNM (CSIC). Authors are indebted to Nicolò Manicardi, Sergi Guixé, and Sergi Vila from IDIBAPS for their skilled assistance. The authors thank current and former members of the GAB Lab and specially Jose Yeste, Gemma Gabriel, and Maria Navarro for their assistance and critical discussions during the development of this study. This work was supported by the Spanish Ministry of Economy, Industry and Competitivity (Explora Project BIO2014-61377 to J. Gracia-Sancho), CSIC (PIE-201450E116 to R. Villa), the CaixaImpulse Program (CI16/00052), Instituto de Salud Carlos III (FIS PI17/00012 to J. Gracia-Sancho), the European Union FEDER Funds, “una manera de hacer Europa,” and the CERCA Program from the Generalitat de Catalunya. CIBEREHD and CIBERBBN are funded by Instituto de Salud Carlos III. Funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. M. Ortega-Ribera and R. Maeso-Díaz received a fellowship from the Instituto de Salud Carlos III (iPFIS IFI16/00016 and iPFIS IFI15/00037, respectively). A. Fernández-Iglesias has a Sara Borrell contract from the Instituto de Salud Carlos III (CD15/00050). Funding text 2 Ministerio de Ciencia, Innovación y Universidades, Grant/Award Number: Explora BIO2014‐61377; CSIC, Grant/Award Number: PIE‐201450E116; Instituto de Salud Carlos III, Grant/Award Numbers: iPFIS IFI15/00037, iPFIS IFI16/00016, CD15/00050, FIS PI17/ 00012; European Union FEDER Funds; Generalitat de Catalunya; CaixaImpulse Program, Grant/Award Number: CI16/00052 Funding text 3 This work was supported by the Spanish Ministry of Economy, Industry and Competitivity (Explora Project BIO2014‐61377 to J. Gracia‐Sancho), CSIC (PIE‐201450E116 to R. Villa), the CaixaIm-pulse Program (CI16/00052), Instituto de Salud Carlos III (FIS PI17/ 00012 to J. Gracia‐Sancho), the European Union FEDER Funds, “una manera de hacer Europa,” and the CERCA Program from the Generalitat de Catalunya. CIBEREHD and CIBERBBN are funded by Instituto de Salud Carlos III. Funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. M. Ortega‐Ribera and R. Maeso‐Díaz received a fellowship from the Instituto de Salud Carlos III (iPFIS IFI16/00016 and iPFIS IFI15/00037, respectively). A. Fernández‐Iglesias has a Sara Borrell contract from the Instituto de Salud Carlos III (CD15/00050)., Peer reviewed